BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sussman NL, Remien CH, Kanwal F. The end of hepatitis C. Clin Gastroenterol Hepatol 2014;12:533-6. [PMID: 24480676 DOI: 10.1016/j.cgh.2014.01.025] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Chhatwal J, Chen Q, Kanwal F. Why We Should Be Willing to Pay for Hepatitis C Treatment. Clin Gastroenterol Hepatol 2015;13:1711-3. [PMID: 26091736 DOI: 10.1016/j.cgh.2015.06.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
2 Chhatwal J, Sussman NL. Universal Screening for Hepatitis C: An Important Step in Virus Elimination. Clinical Gastroenterology and Hepatology 2019;17:835-7. [DOI: 10.1016/j.cgh.2018.12.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
3 Harris M, Ward E, Gore C. Finding the undiagnosed: a qualitative exploration of hepatitis C diagnosis delay in the United Kingdom. J Viral Hepat 2016;23:479-86. [PMID: 26924296 DOI: 10.1111/jvh.12513] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
4 El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology. 2016;64:130-137. [PMID: 26946190 DOI: 10.1002/hep.28535] [Cited by in Crossref: 232] [Cited by in F6Publishing: 213] [Article Influence: 38.7] [Reference Citation Analysis]
5 Harris M. Managing expense and expectation in a treatment revolution: Problematizing prioritisation through an exploration of hepatitis C treatment 'benefit'. Int J Drug Policy 2017;47:161-8. [PMID: 28455145 DOI: 10.1016/j.drugpo.2017.03.015] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
6 Jung J, Feldman R, Kalidindi Y, Riley T 3rd. Association of Direct-Acting Antiviral Therapy for Hepatitis C With After-Treatment Costs Among Medicare Beneficiaries. JAMA Netw Open 2020;3:e208081. [PMID: 32602909 DOI: 10.1001/jamanetworkopen.2020.8081] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Wong JB, Cohen JT. Cost-Effective but Bad for Health? Hepatitis C Treatment, Moral Hazard, and Opportunity Cost. Clin Gastroenterol Hepatol 2017;15:838-40. [PMID: 28259743 DOI: 10.1016/j.cgh.2017.02.026] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Kalidindi Y, Jung J, Feldman R, Riley T 3rd. Association of Direct-Acting Antiviral Treatment With Mortality Among Medicare Beneficiaries With Hepatitis C. JAMA Netw Open 2020;3:e2011055. [PMID: 32692371 DOI: 10.1001/jamanetworkopen.2020.11055] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
9 Rhodes T, Lancaster K, Harris M, Treloar C. Evidence-making controversies: the case of hepatitis C treatment and the promise of viral elimination. Critical Public Health 2018;29:260-73. [DOI: 10.1080/09581596.2018.1459475] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
10 Fisher RA. Living donor liver transplantation: eliminating the wait for death in end-stage liver disease? Nat Rev Gastroenterol Hepatol. 2017;14:373-382. [PMID: 28196987 DOI: 10.1038/nrgastro.2017.2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
11 Kanwal F, Kramer JR, El-Serag HB, Frayne S, Clark J, Cao Y, Taylor T, Smith D, White D, Asch SM. Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus. Clin Infect Dis 2016;63:291-9. [PMID: 27131869 DOI: 10.1093/cid/ciw249] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 6.8] [Reference Citation Analysis]
12 Natarajan Y, Kanwal F. Pay for Performance in Chronic Liver Disease. Clin Gastroenterol Hepatol 2015;13:2042-7. [PMID: 26164221 DOI: 10.1016/j.cgh.2015.06.038] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zuchowski JL, Hamilton AB, Pyne JM, Clark JA, Naik AD, Smith DL, Kanwal F. Qualitative analysis of patient-centered decision attributes associated with initiating hepatitis C treatment. BMC Gastroenterol 2015;15:124. [PMID: 26429337 DOI: 10.1186/s12876-015-0356-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
14 Jung J, Du P, Feldman R, Riley T 3rd. Discontinuation of new hepatitis C drugs among Medicare patients. Am J Manag Care 2020;26:84-8. [PMID: 32059096 DOI: 10.37765/ajmc.2020.42397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015;162:397-406. [PMID: 25775312 DOI: 10.7326/m14-1336] [Cited by in Crossref: 242] [Cited by in F6Publishing: 113] [Article Influence: 34.6] [Reference Citation Analysis]
16 Coughlin SS. "Test, Listen, Cure" (TLC) Hepatitis C Community Awareness Campaign. JMIR Res Protoc 2015;4:e13. [PMID: 25677459 DOI: 10.2196/resprot.3822] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
17 Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS. Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030. J Clin Oncol. 2016;34:1787-1794. [PMID: 27044939 DOI: 10.1200/jco.2015.64.7412] [Cited by in Crossref: 185] [Cited by in F6Publishing: 108] [Article Influence: 30.8] [Reference Citation Analysis]
18 Anand V, Hyun C, Khan QM, Hall C, Hessefort N, Sonnenberg A, Fimmel CJ. Identification and Fibrosis Staging of Hepatitis C Patients Using the Electronic Medical Record System. J Clin Gastroenterol 2016;50:664-9. [PMID: 26974763 DOI: 10.1097/MCG.0000000000000519] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
19 Buzzetti E, Parikh PM, Gerussi A, Tsochatzis E. Gender differences in liver disease and the drug-dose gender gap. Pharmacol Res 2017;120:97-108. [PMID: 28336373 DOI: 10.1016/j.phrs.2017.03.014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
20 Saeed S, Strumpf EC, Moodie EE, Young J, Nitulescu R, Cox J, Wong A, Walmsely S, Cooper C, Vachon ML, Martel-Laferriere V, Hull M, Conway B, Klein MB; Canadian Co-Infection Cohort Study. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada. J Int AIDS Soc 2017;20. [PMID: 29116684 DOI: 10.1002/jia2.25013] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
21 Jung J, Du P, Feldman R, Kong L, Riley T 3rd. Racial/Ethnic and Socioeconomic Disparities in Use of Direct-Acting Antivirals Among Medicare Beneficiaries with Chronic Hepatitis C, 2014-2016. J Manag Care Spec Pharm 2019;25:1236-42. [PMID: 31663464 DOI: 10.18553/jmcp.2019.25.11.1236] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
22 Khan MQ, Anand V, Hessefort N, Hassan A, Ahsan A, Sonnenberg A, Fimmel CJ. Utility of Electronic Medical record-based Fibrosis Scores in Predicting Advanced Cirrhosis in Patients with Hepatitic C Virus Infection. J Transl Int Med. 2017;5:43-48. [PMID: 28680838 DOI: 10.1515/jtim-2017-0011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
23 Harris M, Albers E, Swan T. The promise of treatment as prevention for hepatitis C: Meeting the needs of people who inject drugs? Int J Drug Policy. 2015;26:963-969. [PMID: 26143385 DOI: 10.1016/j.drugpo.2015.05.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
24 Tran L, Jung J, Carlin C, Lee S, Zhao C, Feldman R. Use of Direct-Acting Antiviral Agents and Survival Among Medicare Beneficiaries with Dementia and Chronic Hepatitis C. J Alzheimers Dis 2021;79:71-83. [PMID: 33216031 DOI: 10.3233/JAD-200949] [Reference Citation Analysis]